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Abstract 
 
Currently, the increase of the population suffering from diabetes is one 
problem that most concerns the authorities responsible for public health. A large 
majority of these patients will develop, among other complications, diabetic 
retinopathy, which, in a very advanced state, can lead to blindness. The effects 
of this disease, as is known, are reversible at an early stage and is aiming an 
earlier detection of symptoms that Critical Health launches new software, the 
Retmarker. 
Taking advantage on recent technology (image co-registration) and 
based on studies developed by AIBILI, that reveals the discovery of a new 
biomarker for the progression from an early stage of Diabetic Retinopathy to a 
Clinically Signicant Macular Edema (CSME), the microaneurysm turnover, 
Retmarker, as a tool to help diagnosis, gives us indicators very accurate of the 
possible evolution of the disease. 
 The challenge of this project was to understand the product and all steps 
after its development until it enters the market. Then, Oftaltec using his vast 
market knowledge disclose it and try to place it in the domestic market. 
 This thesis provides a description of the necessary steps to allow the 
product sale and the business strategy to do it. 
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Resumo 
 
Actualmente, o aumento da população que sofre de diabetes é um dos 
problemas que mais preocupa as entidades responsáveis pela saúde pública. A 
grande maioria destes doentes irá desenvolver, entre outras complicações, 
retinopatia diabética, que, num estado muito avançado, pode levar até à 
cegueira. Os efeitos desta doença, como é sabido, são reversíveis numa fase 
inicial e é com o objectivo de uma detecção mais precoce dos sintomas que a 
Critical Health lança no mercado um novo software, o Retmarker. 
Tirando partido de uma tecnologia recente (co-registo de imagens) e 
baseado em estudos do AIBILI, relativamente à descoberta de um novo 
biomarcador para a progressão de um estágio inicial da Retinopatia Diabética 
para um Edema Macular, o turnover de Microaneurismas, o Retmarker, como 
ferramenta de auxilio ao diagnóstico, dá-nos indicadores muito precisos de uma 
possível evolução da doença.   
O desafio deste projecto foi conhecer o produto e todas as etapas 
seguintes ao seu desenvolvimento até à sua entrada no mercado. Aí, a 
Oftaltec, tirando partido do seu vasto conhecimento do mercado, tentará 
divulgá-lo e introduzi-lo no mercado nacional. 
Esta tese fornece uma descrição dos passos necessários para que o 
produto possa ser vendido e a estratégia comercial. 
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1.  Introduction 
 
1.1. Motivation 
 
Diabetic Retinopathy is one of the main causes of blindness in the 
industrialized countries. About 90% of the diabetic patients develop 
retinopathy[1]. 
To enable better and early diagnosis of some retinal diseases, Critical 
Health developed a new software, Retmarker.  
For now, exist the Retmarker C (retinal changes) and the Retmarker DR 
(Diabetic Retinopathy) and they both aim to make a more accurate, and 
automatic detection of the retinal changes. Retmarker DR besides highlighting 
the differences, it also, and mainly, provides the possibility of detect the 
microaneurysms, which presence is an important biomarker for the retinopathy. 
Thus, Retmarker pretends to be a tool that provides ophthalmologists 
more information to support diagnosis. Our main motivation is to improve the 
management of the diseases. 
 
1.2. Objectives 
 
The main intention of this project was to put Retmarker on the market, 
and to achieve that, the project was divided in two different parts: one was to 
know the software, to study it, to know what it was capable to do and suggest 
some possible changes. The second part was to follow all the process of putting 
it into the market (Technical presentation and demonstrations, legal and 
commercial aspects and strategies, etc…). Being in company environment 
would also bring as an objective to take contact with the area of retina diseases 
and diagnosis devices. 
 
1.3. Scope  
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This project was developed in the scope of the Master integrated in 
Course of Biomedical Engineering, taught on the Physics Department of the 
University of Coimbra. This project was realized in partnership with Oftaltec and 
Critical Health. 
 
1.4. Audience 
 
This project is addressed to the supervisors and jury members, and 
possible future students that may continue this project and general readers 
interested in retinal diseases and diagnosis. 
 
 
1.5. Document Structure and Organization 
 
This document is divided in nine chapters. 
The aim of the present chapter is to introduce the reader to the project 
motivation and objectives. 
The next one, Project Management, provides information about the 
project organization, such as project members and their functions. It also 
provides a brief summary about Oftaltec and Critical Health. 
On the third chapter is described the scientific background that supports 
the software.  
The fouth chapter provides the reader with an overview about the the 
state of art in retinal diseases dignosis.  
 On the fifth chapter we talk a little about the studies performed in AIBILI 
related with Retmarker. 
Chapter 6 – How does Retmarker works? – is the description in detail of 
the software. 
Chapter 7 is about some tests validation tests and market studies carried 
out by Critical Health. 
In chapter 8 are described the steps to achieve the CE marking. 
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Table 1. Project Members 
Chapter 9 is where is explained the strategy to sell Retmarker, and in the 
tenth we refer the awards won by Retmarker. 
In the last chapter, the conclusion, is drawn a brief appreciation about the 
project and the possible future works. 
 
 
2. Project Management 
 
2.1. Project Members 
The project was developed by a Biomedical Engineering student of the 
Faculty of Sciences and Technology, University of Coimbra and their 
supervisors.  
The student was responsible for all the study related to Retmarker. The 
supervisors accompanied the project evolution and individual development of 
the student, being responsible for the orientation and coordination of his work.  
The elements that composed the team are presented in the table. 
 
Name  Contribution Contact 
Carlos André Neves Student andrecneves@hotmail.com 
Professor José Paulo Domingues Coordinator jpd@fis.uc.pt 
Dr. Afonso Martinho Coordinator afonsomartinho@oftaltec.pt 
Eng. Frederico Teles Supervisor ft-santos@critical-health.com 
Eng. João Diogo Ramos Supervisor jramos@critical-health.com 
Eng. João Pinto Supervisor jp-pinto@critical-health.com 
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2.2. Project Supervising 
The project was supervised by two entities, Oftaltec, and Critical Heath. 
 
 
2.2.1. Supervising at OFTALTEC  
 
It stands out for the highly sophisticated equipment that sells, which are 
developed based on the most advanced technologies. It has market leadership 
in some business areas, for example in refractive surgery. Oftaltec represents 
exclusively several manufacturers such as Heidelberg Engineering or 
Technolas. 
The company has a commercial department, a clinical application 
department and a technical department. The technical department is composed 
by three technicians with specific training given by the manufacturers. 
 
 
2.2.2. Supervising at CRITICAL HEALTH  
 
Critical Health is a spin-off of Critical Software created in 2008 to 
continue the healthcare activities started in 2006. Critical Software is 
specialized is real-time systems for defense, aerospace and 
telecommunications. 
Since it was created, Critical Health has tried to create solutions capable 
of reducing healthcare spending and accessible to everyone. 
The company objectives are: 
To develop solutions to help to prevent Loss Vision of Mobility and 
Cognitive skills for diabetics and people with more than 65 years old and to 
build Technological Partnerships with Internationally Institutions 
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Figure 1. Human eye 
Critical Health works in two different business areas: 
 Vision 
In this department the gold is to develop solutions for retinal diseases like 
Diabetic Retinopathy, Age-related Macular Degeneration or Glaucoma. 
Retmarker was the first to be concluded and it is useful to monitor the 
progression of Diabetic Retinopathy. Analyzing fundus photos, it provides 
additional information that helps the doctor in his diagnose.  
 Health Monitoring 
In this division Critical Health is developing software to monitor patients 
ECG, fall detection and their location. The patients wear necklaces or bracelets 
and the device quickly alerts the caregivers. The system is being developed 
directly with customers. 
 
3. Scientific background 
3.1. The human eye 
The human eye is an almost spherical structure with a diameter about 
24mm. It is divided in three layers: the outer layer 
composed by sclera and cornea (tunica fibrosa); 
choroids, ciliar body and iris are the middle layer 
(tunica vasculosa) and the inner layer is composed 
by the retina and the retinal pigment epithelium. 
The external coat of the eye is the sclera and it occupies about 80% of 
the surface of the human eye. Sclera function is to maintain the spherical shape 
of the eye, besides the protection of the inner structures. Cornea acts as the 
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eye's outermost lens. Its function is to control and focus the entry of light into 
the eye. 
In the tunica vasculosa, the major part of the layer is occupied by the 
Choroid. It is a thin black membrane of blood vessels (so avoids the light 
reflection) whose main is to provide blood. 
The other constituents of the midlle layer are the Ciliary body and the iris. 
The Ciliary body goes from the Choroid to the Iris.  
The lens is transparent structure whose main purpose is to focus light 
rays onto the retina. To do that correctly, the shape of the lens has to be 
changed depending on the object‘s distance. The change is done by the ciliary 
muscles. Iris is the visible colored part of the eye. It is a muscular contractile 
structure that surrounds the Pupil. Pupil is the dark center opening in the center 
of the iris.  It changes size to adjust for the amount of light available.  
The retina is the inner layer of the eye and it is divided in photoreceptive 
part and non receptive one: the non-sensory (non-receptive), the posterior part 
of the retina has a retinal pigmented epithelium which transports metabolic 
wastes from photoreceptors to the choroids. The photoreceptor cells can be of 
two types: rods or cones and the distribution of each of these types it‘s not the 
same all over the retina. Cones are responsible for color vision while rods are 
responsible for the vision with reduced light. Macula lutea is an area in the 
retina that contains special light-sensitive cells, cones. They allow us to see fine 
details clearly in the center of our visual field. 
As we move away from the center of the retina the cones decrease. The 
optic disk is a region in the retina where occurs the insertion of the optic nerve, 
a bundle of more than a million nerve fibers that carries visual messages from 
the retina to the brain. Here does not exist any type of photoreceptor cells, thus 
the optic disk location is usually called the blind spot,[1], [2]. 
 
 
3.1.1. How eye works 
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The eye is a very complex organ and in the visual processing all its parts 
play an essential role. 
If a person is looking at a car the light rays are reflected off it and enter 
the eye through the cornea (transparent outer coating of the eye). 
The cornea refracts the rays and they pass through the pupil. The 
colored part that surrounds the pupil, the iris, regulates the amount of the light 
that passes through. In bright light, iris reduces pupil‘s size to prevent too much 
light from entering. In dim light, the pupil enlarges to receive more light. 
After this, the rays light reach the crystalline lens. The lens is important 
because they refract the rays and focus them in the retina. The ciliary muscles 
of the eye can contract and relax to change lens shape. If the object is close, 
the muscles contract and the lens become rounder. If it is distant, the muscles 
relax and the lens flattens. This feature of the lens allows a perfect vision at 
different distances.  
In the back of the eye there is the retina. It occupies two-thirds of the eye 
wall and is responsible for the wide field of vision. If light rays focus directly on 
the retina we get a perfect vision. If light focuses in front of or behind the retina, 
the result is blurry vision.  
The retina function is to transform light rays into electrical signals and 
transmit them to the brain through the optic nerve. This is achieved by the 
millions of photoreceptor cells called rods and cones. Rod cells (110 – 125 
millions) allow mesopic and scotopic vision (twilight and night vision) and the six 
or seven million cones respond to bright light and enable to see in color. 
The major part of the cones is in the macula. The central part of the 
macula, fovea, has the highest concentration. The outer portion is the primary 
location of rods.  
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The signals are transmitted 
from the cones and the rods to 
the brain by the optic nerve. The 
signals transmitted by each eye 
correspond to a slightly different 
image. Once they reach the brain, 
they are and combined to form 
just one image. [3]. 
 
 
3.2. Retina 
The retina is the innermost of three layers of the globe. It is a very thin 
and transparent membrane and is divided in two different parts: photoreceptive 
part and non receptive one,[4]. 
The photoreceptive part consists of nine layers: 
1. Internal limiting membrane (glial cell fibers separating the retina from the 
vitreous body ) 
2. Nerve fiber layer (axons of the third neuron) 
3. Ganglion cell layer (cell nuclei of the multipolar ganglion cells of the third 
neuron; ― data acquisition system‖) 
4. Inner plexiform layer (synapses between the axons of the second neuron 
and dendrites of the third neuron) 
5. Inner nuclear layer (cell nuclei of the bipolar nerve cells of the second, 
horizontal cells, and amacrine cells) 
6. Outer plexiform layer (synapses between the axons of the first neuron 
and dendrites of the second neuron) 
7. Outer nuclear layer (cell nuclei of the rods and cones= first neuron) 
8. Outer limiting membrane (sieve-like plate of processes of glial cells 
through which rods and cones project) 
Figure 2. Schematic section through the human eye 
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9. Layer of rods and cones (the actual photoreceptors) 
 
 
 
 
 
 
 
 
 
 
The non receptive part consists of two layers: 
 
1. Retinal pigment epithelium (a single cubic layer of heavily pigmented 
epithelial cells) 
2. Bruch‘s membrane (basal membrane of the choroid separating the 
retina from the choroid) 
 
3.3. Retinal diseases 
Retina can suffer from a lot of diseases but the ones that we are more 
interested in are those which symptoms we can diagnose using retinographies. 
And the retinal changes that we can observe in a retinography are among 
others: haemorrhages, hard exudates, drusen and microaneurysms. 
These changes are symptoms of retinal diseases such as Age-related 
Macular Degeneration, and Diabetic Retinopathy,[5]. 
 
3.3.1. Diabetic Retinopathy 
Diabetic Retinopathy is the disease that we are going to pay more 
attention. 
Figure 3. Photoreceptive layer 
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Figure 4.  Non proliferative retinopathy 
It is one of the main causes of blindness in industrialized countries and 
after 15 years of suffering from diabetes, approximately 2% of the people 
become blind, and about 10% develop severe visual damages. 
Diabetes is a disease that damages retina blood vessels because of the 
high levels of glucose. The walls become thicker but also weaker, which leads 
to deformation and leakage, so a good blood sugar control is very important to 
control the disease. In general, the retinopathy is not developed until at least 10 
years after the onset of disease. 
Diabetic retinopathy appears in patients with type 1 and type 2diabetes 
but in different ways. 
In patients with type 1 diabetes the 
vision loss is due to the formation of new 
vessels (proliferative retinopathy), while in 
type 2 diabetes vision losses are most 
commonly due to macular edema and 
proliferative retinopathy is relatively rare. 
 
Diabetic retinopathy is characterized by specific alterations in the 
appearance of the retina. The first change that can be seen is the 
microaneurysm. Besides this, retinal blot hemorrhages, hard-exudates, cotton-
wool spots and intraretinal microvascular abnormalities are some of other 
lesions that can be found in non proliferative phase of diabetic retinopathy. 
In diseases‘ early stages, it doesn‘t cause blindness. The hemorrhages 
can distort parts of visual field or, blur the vision if they are near the macula. 
In non-proliferative retinopathy, retina can thicken and if it occurs in the 
macula we are in the presence of a progression to a Clinically Significant 
Macular Edema (CSME). The nervous tissue can‘t work properly due to this 
thickening and cause vision damages.  
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Table 2. Retinal Changes in Diabetic Retinopathy, adapted from Lang, g., 
Ophthalmology. A pocket textbook atlas. 2004 
Figure 5. Proliferative Retinopathy 
 
In the proliferative retinopathy, the growth of new vessels may seem 
beneficial, but is not. These new vessels are weaker and grow abnormally. In 
some cases they can cause a retinal detachment. Proliferative retinopathy is the 
most dangerous and can cause serious damages like near total blindness and 
in extreme cases even total blindness. 
 
 
 
 
 
 
 
Stage of 
retinopathy 
Retinal changes 
Non-proliferative diabetic retinopathy 
1. Mild  At least one microaneurysm, retinal hemorrhages, 
hard exudates 
2. Moderate   Mild intraretinal microvascular abnormalities (IRMA) 
in four quadrantes of the retina  
 Moderate hemorrhages in two or three quadrants 
 Venous hemorrhages in four quadrants 
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3. Severe  Moderate hemorrhages in four quadrants 
 Venous beading in two quadrants 
 Moderate IRMA in one quadrant 
Proliferative diabetic retinopathy 
1. Mild  New vessels elsewhere (NVE) ‹ 0.5 of the disc area 
in one or more quadrants 
2. Moderate  NVE ≥ 0.5 of the disc area in one or more 
quandrants 
 New vessels on the disc (NVD) < 0.3 – 0.25 of the 
disc area 
3. High risk  NVD ≥ 0.3 – 0.25 of the disc area 
 Vitreous hemorrhage with any new vessels 
 
Treatment 
Does not exist a definitive treatment to diabetic retinopathy. The most 
common solution is the surgery but it is not a cure. Even after surgery, it is 
required a close monitoring and some times more treatments may be also 
needed. 
The choice of the treatment depends on the stage and on the type of 
diabetic retinopathy that the patient had developed.  
Early diabetic retinopathy 
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Usually in an early stage of non proliferative diabetic retinopathy the 
patient does not receive immediate treatment. In these stages a good sugar 
control is enough to slow the progression.  
Advanced diabetic retinopathy 
When the disease is in an advanced stage, the solution is surgical 
treatment as soon as possible. Depending on the specific problem the surgery 
performed can be: 
 Focal laser treatment. This laser treatment, also called 
photocoagulation, can stop or slow the leakage of blood and fluid in the eye. 
During the procedure, leaks from abnormal blood vessels are treated with laser 
burns.  
 Scatter laser treatment.   This laser treatment, also known as panretinal 
photocoagulation, can shrink the abnormal blood vessels. During the procedure, 
the areas of the retina away from the macula are treated with scattered laser 
burns. The burns make the abnormal new blood vessels shrink and scar.  
 Vitrectomy.  This treatment can be used to remove blood from the 
middle of the eye as well as any scar tissue that's tugging on the retina. Scar 
tissue and blood in the eye are removed and replaced by a salt solution, which 
helps to maintain eye's normal shape. Vitrectomy may be followed or 
accompanied by laser treatment. 
Besides treatments, researchers are trying to develop medications to 
prevent the abnormal blood vessels formation in the eye. This medication can 
be directly injected in the eye,[6],[7] . 
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Figure 6. Normal Vision Figure 7. Vision with Diabetic Retinopathy 
 
 
  
 
 
 
 
 
3.3.1.1. Relevant symptom in Diabetic Retinopathy: Microaneurysm 
 It is widely accepted that the earliest clinically recognizable sign of 
diabetic retinopathy is the microaneurysm (MA). These are small round dark red 
dots on the retinal surface that are less than the diameter of the major optic 
veins as they cross the optic disc. 
Increasing numbers of microaneurysms are associated with capillary 
occlusion leading to retinal ischemia (lack of oxygen) and progression of 
retinopathy[8]. 
3.3.2. CSME 
CSME (Clinically Significant Macular Edema) was defined according to 
the Early Treatment Diabetic Retinopathy Study classification protocol as the 
presence of retinal thickening at or within 500μm of the center of the macula or 
hard exudates at or within 500μm of the center of the macular if associated with 
thickening of the adjacent retina and/or zones of retinal thickening 1 disc area in 
size, at least part of which being within 1 disc diameter of the center. An early 
diagnosis is extremely important to avoid the disease progression to this stage.  
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Laser treatment is normally the solution when the disease is in an 
advanced stage,[9]. 
 
 
 
 
 
 
4. State of art 
 
Actually, two of the most important exams using retinal images are the 
angiographies and the retinographies. They are different and complementary for 
some diseases. 
 
4.1. Angiographies of the retina 
Retinal angiography is a diagnostic procedure that photographs the 
retinal fundus. Normally it is performed when the ophthalmologist pretends to 
identify blood vessels that may be damaged. This diagnostic procedure consists 
in the injection of a small amount of dye in the circulatory system through a vein 
in the arm and posterior analysis of the image when the dye reaches the retinal 
vessels. 
After the injection, it is possible to photograph the retinal fundus and 
easily observe the vessels filled with the tracer. It enables a more detailed 
analysis of the distribution of the dye and obviously of the evolution of the retinal 
vessels.  
Figure 8. Eye with CSME 
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If the dye used is fluorescein it is called a fluorescein angiography. If the 
dye used is indocyanine it is called an indocyanine green angiography.  
In the performance with fluorescein, the eye is illuminated with blue light 
and that allows a maximum excitation of the tracer. When excited, the 
fluorescein fluoresces in the yellow-green wavelengths. The light emitted is then 
filtered and only the yellow-green light reaches the camera. The images 
acquired are grey scaled images. When the dye reaches the vessels of the 
retina, it becomes possible to identify some white regions that are the vessels 
where the dye circulates. 
Diabetic retinopathy, between others diseases, affects the retinal 
circulation and the fluorescein angiography is essential to diagnose it. In other 
eye disorders, such as age-related macular degeneration, it is mandatory to do 
an indocyanine green angiography because leakages are in the choroidal blood 
vessels. 
The two dyes have the same purpose but for different parts of the retina. 
The indocyanine green reaches its maximum excitation when it is illuminated by 
infrared light and fluoresces with infrared light too. Thus, this allows that the 
infrared light emitted from the choroids vessels reaches the camera. The 
infrared light is not visible, so are used high-sensitivity digital cameras in 
infrared spectrum,[10]. 
 
4.1.1. Spectralis HRA 
A step ahead of the commom angiographies cameras is the Spectralis. It 
is a device manufactured by Heidelberg Engineering (German company) and 
sold by Oftaltec. There are 3 different Spectralis: the HRA, the OCT and the 
HRA+OCT. 
All the devices from the Spectralis line are diagnostic tools and produce 
various types of retinal images of the human eye. They support the 
evaluationand treatment of different diseases of the posterior segment, such as 
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related macular degeneration with age, diabetic retinopathy and 
glaucoma. We are going to describe a little bit the Spectralis HRA (Heidelberg 
retina angiograph)[11],[12]. 
 
4.1.1.1. Description  
Confocal scanning laser is replacing digital cameras because they add 
motion, depth, and clarity to fundus imaging. Instead of difficulties to control 
random white light from a flash, lasers enable exact location and ideal 
wavelength selection. 
The detail and perspective that laser imaging with the HRA provide are 
far away better than in photography, whether digital or film. This is achieved 
because of the in the properties of confocal scanning laser technology which 
enable wavelength-selective imaging and fast scanning speeds enabling 16-
frame-per-second motion images. 
So, this equipment is an ophthalmoscope confocal scanning laser used 
in angiographic exams of the retina and is able to do the diagnosis by detecting 
reflected light. it allows use the following imaging techniques: 
 Fluorescein or fluorescein angiography (FA) 
 Indocyanine green angiography (ICGA) 
 Reflectance infrared (IR = "infrared") 
  Reflectance without the red or blue (RF = "redfree)  
 fundus autofluorescence (AF) 
 Simultaneously FA and ICGA 
 Simultaneously FA and IR 
 Simultaneously ICGA and IR 
  Simultaneously AF and IR 
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Table 3. Light Sources 
With each of the imaging techniques mentioned above , can be picked up 
and saved individual images or image sequences. 
 
4.1.1.2. Light sources 
The dyes are excited with the bands wavelengths relatively narrow. The 
use of laser is the most efficient excitation, since all power is concentrated in a 
particular wavelength, and not in a relatively broad continuum, as is the case 
of conventional flash photography. The laser light sources of the Spectralis 
emit three different wave lengths: 
 For the excitation of fluorescein, it uses a solid-state blue laser 
(Wavelength equal to 488nm). A filter band eliminator separating the 500nm 
excitation light of fluorescent light emitted. The same wavelength is also used 
(no filter eliminator) to generate images by blue reflectance. Furthermore, they 
can acquire with the Spectralis HRA auto fluorescence images (488nm) of high 
quality. 
 For the excitation of indocyanine green, it uses a laser diode with a 
wavelength of 790nm, equipped with an 830nm filter eliminator separation of 
the exciting light of fluorescent light emitted. 
  A second laser diode with a wavelength of 820nm is for 
imaging by infrared reflectance (IR). 
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4.1.1.2. Confocal Scanning Laser Ophthalmoscope 
 
The confocal ophthalmoscope is a device that allows visualization of the 
retinal fundus.  
To illuminate it the light source used is a laser. The laser is targeted to 
the retina‘s part you want to analyze. The light reflected off the retina is then 
divided from the incident light and a beam splitter deflects it to a detector. This 
allows the measurement of only the light reflected at different points. 
In a confocal optical system a small diaphragm is placed in front of the 
detector where its position is optically coupled with the focal plane of the lighting 
system. The confocal hole is important to focus the light reflected off the eye. 
The confocal hole only focus the light reflected directly to it and this way only a 
part of the light is detect by the photodetector. Thus, with a confocal scanning 
system can be observed images with very good resolution. 
 
In what concerns to Diabetic Retinopathy, the angiographies are the gold 
standard exam due to the ease to detect microaneurysms (hallmark of the 
disease). But angiographies are an invasive exam and are not tolerated by all 
the patients. Thus, AIBILI developed some studies (will be detailed later) and 
Figure 9. Spectralis HRA 
Figure 10. Quality different between images from a 
Spectralis HRA and a normal digital camera 
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achieved a new Biomarker for Diabetic Retinopathy that can be found with the 
same reliability using retinographies. 
 
 
 
 
 
 
 
 
 
 
4.2. Retinographies 
Retinography is an exam performed by ophthalmologists and consists in 
the acquisition of color photographs of the retinal fundus and it is done with a 
fundus camera. 
The patient‘s eye is illuminated with white light and photographed.  
It is also possible to illuminate the eye with green light, instead of white one. It‘s 
called a red-free retinography. These images are almost completely dark 
images with the vessels in darker colors than the retina surface and the optic 
disk region is near white colored. This type of retinography provides better 
contrast between the vessels and the retina surface than the color colored one. 
Retinographies are normally used to see the evolution of diseases like 
diabetic retinopathy, macular degeneration and ocular tumors because thought 
these images we are able to identify symptoms such as haemorrhages, hard 
exudates situations, vasodilatation, drusen and microaneurysms,6]. 
Figure 11. Schematic Confocal Scanning Laser Ophthalmoscope  
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Figure 12. Red-free Retinography 
 
 
 
 
 
 
 
4.2.1. Color fundus camera 
All the fundus cameras operate in a similar way. Either the viewing bulb or the 
electronic flash, pass through several beam splitters, mirrors and lenses before 
passing through the cornea until reach the retina. 
The light paths of incident and reflected light are independent, so, there are 
minimal reflections of the light source captured in the image. 
The image forming rays directs to the telescopic eyepiece. When the picture is 
taken, a mirror cuts the path of the illumination system and allows the light from 
the flash bulb to pass into the eye. Simultaneously, another a mirror redirects 
the light onto the capturing medium, whether it is film or a digital CCD. 
The quality of the image achieved through the fundus camera is great, allowing 
a clear vision of the retina. Usually, cameras have a power of magnification of 
2.5X and the image angle is about 30°.   
It allows several exams, such as: color and red-free photographs and 
angiographies,[13],[14]. 
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Figure 13. Screening for Diabetic Retinopahty using a digital fundus camera 
 
 
 
 
 
 
 
 
 
 
5.  Studies carried out AIBILI 
This research institute has been developing an amazing work in the early 
prediction of the diabetic retinopathy. 
They have done several studies that confirm the new biomarker that 
supports Retmarker DR: the microaneurysm turnover.  
In a paper published in 2009 they present an innovative method that is able 
to perform reproducible and meaningful assessmentof microaneurysm turnover 
by mapping the specific location of each microaneurysm, registering its exact 
coordinates in the ocular fundus. 
In the study were included 47 patients with type 2 diabetes and mild non 
proliferative diabetic retinopathy from 43 to 70 years old. They were followed up 
every 6month over a 2 year period. In each of the visits were performed color 
fundus photograph and fluorescein angiography (the gold standard exam for 
microneurysm detection). 
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The essential tool of this study is the MA – Tracker. It is an algorithm that 
enables the manually microaneurysm earmarking.  
First it processes the images to extract the Region of Interest (ROI) and to 
enhance the images to make easier the microaneurysm detection. The step is 
the image co-registration. The images are overlapped in relation to the first visit. 
Last, in both type of examinations the microaneurysms are marked 
manually. The co-registration of the images enables to mark the 
microaneurysms in the baseline image and to identify the visit in which it 
appeared. 
Analyzed the results, was verified that the microaneurysm turnover was 
more reliable than the simple count. It was shown that the microaneurysms no 
not remain stable between visits. Since the number of microaneurysm didn‘t 
vary that much between the visits, the simple count could suggest that the 
disease was stable. The microaneurysm turnover showed that microaneurysms 
do not remain stable from one visit to another. The number of microaneurysms 
could be similar but the formation and disapearence rates were much higher, 
which shows that the disease is progressing more rapidly.   
Another important conclusion was that although fewer microaneurysms 
were found in the fundus photograph in comparison to the angiographies, there 
was an agreement in the turnover between both exams.  
Therefore, this study shows that increased formation rates of 
microaneurysms appeared to be more reliable then the count for the diabetic 
retinopathy progression and that this can be obtained from color fundus 
photograph[15]. 
 
In the same year, another study, using retinographies and the MA – tracker 
they could prove that, for patients with the same problem, the microaneurysm 
turnover was a reliable indication for aggravation of the disease to a CSME. 
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This was a 10-year follow-up study. Using the MA – tracker were analyzed 
data from 113 patients with mild-to-moderate non proliferative Diabetic 
Retinopathy during the first 2 years to observe the Microaneurysm turnover. In 
the last 8 years was monitored the occurrence of Clinically Significant Macular 
Edema (CSME).  
Thanks to the MA – tracker, the microaneurysm turnover can the computed 
and was found that a formation rate of at least 2 microaneurysms/year indicates 
that these patients require closer monitoring because they have a higher  risk of 
progression to CSME. 
From the 17 patients that developed CSME, 12 of them had a 
microaneurysm turnover of at least 2 microaneurysms per year which is a 
significant result[16]. 
So, this study shows that microaneurysm turnover in color fundus 
photography is a good biomarker of diabetic retinopathy progression. 
 
6. How does Retmarker works? 
Retmarker uses color retinographies, which are a widespread tool for 
diagnosis of retinal diseases; it uses a proprietary co-registration algorithm 
which automatically overlaps the images. 
Retmarker has two modules: the Differences Analysis and the 
Microaneurysm Analysis. We are going to focus on Retmarker DR because it 
has the Differences Analysis module that exists in Retmarker C and also does 
the microaneurysm detection.  
 
6.1. What are the inputs? 
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As it was said before, Retmarker works only with retinographies. They 
are cheap and in comparison with angiographies they are advantageous 
because they are non-invasive. 
These should be 45° or 50° retinographies, centered on the posterior 
pole (field 2). Retmarker was extensively tested with Mydriatic images. 
Retmarker also works with Non-Mydriatic exams but it requires some additional 
care when choosing the images to analyze. 
Every fundus camera's software allows exportation of the exams‘ images 
in different formats. Retmarker was tested with images from KOWA, Canon, 
Zeiss and Topcon fundus cameras  with TIF and JPEG formats; others formats  
may also work. The minimum size accepted is 768px x 578px. 
Additionally, the retinographies should have been taken with the same 
fundus camera device. 
6.2. What‘s the procedure? 
 
Retmarker is a very simple and intuitive software.  
When we initiate the software you immediately see an authentication 
system which is very useful if you for example have a server license. 
Then we have a panel where we can select to see all the patients listed, 
add another, search one by name and also a select a dashboard with the 
analysis that were performed but not seen yet. 
When we make the registration of a patient, besides all the identity and 
contacts      data it is possible to make a full clinical history; previous surgeries, 
laser treatments, if he suffers from myopia, tumors, etc. 
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Figure 14. Comparison side-by-side of the images in the differences analysis 
The next thing to do is create the image database. Click on ―add images‖ and 
we can import them easily. OD (oculus dexter) to right eye retinographies, OS 
(oculus sinister) to the left. 
The images must be from the same patient, same eye and same angle 
definition, otherwise, Retmarker can‘t complete the analysis. 
 
 
6.2.1. Differences Analysis 
 
To perform a difference analysis, we need obviously at least two 
retinographies. Even if we have more, all the images are compared against the 
baseline one. We can choose which image we want for baseline. With the 
differences highlighted, we can see the evolution of the eye over time.  
This way it makes possible to the doctor to focus on the areas where the 
differences are marked. It identifies details that are difficult to the human eye to 
observe. Retmarker only shows the differences; it doesn‘t classify them as a 
symptom. 
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Figure 15. Retinography with the changes marked 
 
 
 
 
6.2.2. Microaneurysm Analysis  
In the early stages, diabetic retinopathy lesions are reversible but it is 
hard to detect the disease because it remains asymptomatic for a long time. 
Regarding the studies develop by Aibili the Microaneurysm (MA) turnover 
is a new and even more reliable Biomarker for the Retinopathy progression to 
CSME than the simple count. 
And it is the microaneurysm detection and posterior calculation of the MA 
turnover that makes Retmarker DR innovative. It is capable of detecting each 
microaneurysm as a single entity in a specific position allowing to calculate the 
turnover (formation and disappearance ) ratios. 
Considering the reliability of the MA turnover, Retmarker DR should be 
used in early stages – ETDRS level < 35. 
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Table 4. The ETDRS scale and severity of retinopathy 
ETDRS retinopathy level Severity of retinopathy 
10 None 
20 Microaneurysms only 
35 Mild NPDR 
43 Moderate NPDR 
47 Moderately severe NPDR 
53a-d Severe NPDR 
53e Very severe NPDR 
61 Mild PDR 
65 Moderate PDR 
71,75 High-risk PDR 
81,85 Advanced PDR 
 
To perform a Microaneurysm Analysis, we need at least 3 images. In this 
case, the comparison is made with the previous image. The prediction of 
diabetic retinopathy progression using MA turnover as biomarker, has a very 
good accuracy for a follow-up every 6 months over 1-2 years. 
The software detects every microaneurysm as a single entity in a specific 
location. This way it can tell us if the microaneurysm has disappeared (marked 
with a yellow circle), if it is new (red circle) or if it is already existed (green 
circle).At the same time it calculates the MA formation and disappearance rates.  
As it is said in the study carried out by Aibili, a patient with a formation rate 
superior to 2 microaneurysms per year needs a closer monitoring because it is 
likely that the disease progresses to a CSME. 
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Figure 16. Evolution of the microaneurysms over time 
Figure 17. Formation and disappearance rates  
 
 
 
 
Besides these two types of analysis, Retmarker also enables to store 
clinical information about the patients and has links to practice guidelines.  
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As we can see, in both analyses, it is possible to perform a side-by-side 
comparison up to 4 images. 
 
6.3. Which are the advantages? 
 Retmarker brings a lot of benefits, both clinical and in business.  
 Clinical Benefits:  
1) Automatic detection of retinal changes 
2) Is a powerful tool in the early diagnosis of the diabetic retinopathy. 
 Business Benefits: 
1) Improves care quality because the results that it gives are very      
precise  
2) Improves care delivery because the results are fast and effortless 
3) Provides a digital imaging archive 
 
7. Validation tests and Market studies 
Validation tests 
To ensure that the results given were reliable Retmarker, were carried 
out several tests. 
Images co-registration: validation performed based on the KPI (key 
performance indicator) analysis of the overlapping factor of vessels from the 
various fundus photographies  
Differences Detection: comparing of the results obtained by the algorithm 
and a ground-truth designed by AIBILI experts 
Microaneurysms detection: comparison of the results against a ground-
truth of AIBILI experts 
  
Launch of the application Retmarker  31 
 
Microaneurysms Turnover Concept: based on the comparison between 
the results achieve by the software and the scientific studies made by AIBILI 
and confirming that the results were in line with the results of those studies, 
more specifically, the microaneurysms detection and the calculation of the 
Formation Rate. 
 
 
Market Studies*: 
 
Two market researches were made by the company IMS Health. 
The first one, in 2007 aimed to collect information on the use of 
retinographic equipment and its different types (type of photo, camera 
characteristics, parameters for the export of image,… ) in several European 
countries. 
The second one, more recently, was a conjoint analysis, that based on 
focus groups, qualitative and quantitative interviews, had has purpose to define 
the pricing policy of the product, taking in account the policy/ objectives of 
Critical Health and in consideration the value given by the users in the various 
segments of potential clients. This work was developed in Portugal, United 
Kingdom and Germany. 
 
 
8. CE Marking 
After all the development of the software, there is still a lot of work to do: put 
it in the market. And the first step is to get the certification according to the 
Medical Devices Directive and consequently the CE marking. 
When a company develops a product and pretends to sell it in the European 
Union it needs the CE marking mandatorily.   
CE is a french acronym that means Conformité Européeneé and indicates 
that the product respects all the directives defined by the European Union and 
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Figure 19. CE Marking 
his way it can be commercialized in all the European Economic Area composed 
by 30 countries. 
 
 
 
 
 
 
 
 
Usually the medical devices use the CE marking plus 4 digits ―CExxxx‖. 
The 4 digits correspond to the Notified Body once is required a conformity 
assessment performed by this Notified Body.  
So, to be certified, the product has to fulfill the European Union 
directives. The one that regulates medical devices is the 93/42/CEE. 
The free movement of goods is one of the single market freedoms of the 
European Union. Since January 1993, were suppressed checks of the traffic of 
goods on the domestic market and since then, the EU emerged as a single 
territory, without borders. 
So, there was the necessity of standardize the directives from each 
country to a single one.   
The medical devices directive 93/42/CEE was created back there and 
posteriorly has been updated. 
The last amendment was the directive 2007/47/EC and became 
mandatory on 21 March 2010. 
The first thing to do in order to obtain the CE marking is to check if the 
product is a medical device is to confirm that it fits in the new definition. 
 
This way, according to Directive 2007/47/EC Medical Device means: ―any 
instrument, apparatus, appliance, software, material or other article, whether 
used alone or in combination, including the software intended by its 
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manufacturer to be used specifically for diagnostic and/or therapeutic purposes 
and necessary for its proper application, intended by the manufacturer to be 
used for human beings for the purpose of:  
 diagnosis, prevention, monitoring, treatment or alleviation of disease,  
 diagnosis, monitoring, treatment, alleviation of or compensation for an 
injury or handicap,  
 investigation, replacement or modification of the anatomy or of a 
physiological process,  
 control of conception,  
,and which does not achieve its principal intended action in or on the human 
body by pharmacological, immunological or metabolic means, but which may be 
assisted by such means‖. 
After the conclusion that it fits within the medical device definition the 
next step is to classify the software. 
Medical devices are divided in Class I (Is and Im), Class IIa, IIb and III. 
The higher the classification the greater the level of assessment required and 
the risk associated. 
The rules to classify medical devices are explained in Annex IX of the 
directive 93/42/EEC. The classification of a medical device depends on some 
factors such as:  
 how long the device is intended to be in continuous use 
 if it is or not invasive or surgically invasive  
 if the device is implantable or active  
 if it contains a substance, which in its own right is considered to be a 
medicinal substance and has action ancillary to that of the device 
Retmarker was considered a Class 2a Medical Device. 
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In order to obtain the device compliance as a class IIa there are some steps 
that are needed: 
1. Classification: ensure the device is a Class IIa medical device.  
2. Choose Conformity Assessment Route. 
3. Compile the Technical File.  
4. Obtain certification from a Notified Body  
5. Declaration of Conformity.  
6. Vigilance and Post Market Surveillance. (affix CE marking & market the 
products)  
Class IIa Medical Devices: Conformity Assessment Routes 
Class IIa devices manufacturer‘s besides the declaration of conformity 
with the provisions of the Directive and Regulations that ensures that his 
products comply with relevant Essential Requirements, they need to back up 
this declaration with conformity assessment by Notified Body. The manufacturer 
can choose which assessment he wants: 
1. follow the procedure related to the EC declaration of conformity set out in 
Annex II (full quality assurance) 
or  
2. follow the procedure related to the EC declaration of conformity set out in 
Annex VII, coupled with either:  
 the procedure related to the EC verification established in Annex IV; 
or 
 the procedure related to the EC declaration of conformity established in 
Annex V; 
or 
 the procedure related to the EC declaration of conformity established in 
Annex VI.  
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The manufacturer can CE mark his product and sell it after the Notified Body 
gives him the certification. 
The notified Body that made all the certification was Tüv Rheinland. It was 
made according the annex II (procedure 1). After the audition to the system, all 
was according to the standards required (ISO 13485) and ,finally, Retmarker 
received the CE marking ―CE0197‖,[17],[18-19]. 
 
 
 
9. Versions available  and Strategies to sell it 
Retmarker is available in the following options: 
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Table 5. Retmarker versions 
 
Retmarker C Individual 250 analysis package 
Desktop License (unl. 
use) 
Corporate Server License (unl. 
use) 
Retmarker DR Individual 250 analysis package 
Desktop License (unl. 
use) 
Corporate Server License (unl. 
use) 
 
There were 868 Ophthalmologists in Portugal in 2009 and among those 
few are retina specialists, [20].  
The Retmarker is a tool that will support mainly the non retina specialists. 
Those are our main market and particularly the ones that have a color fundus 
camera in their practice.  
This way, whenever they are confronted with a retinopathy, they can 
send the patient to a specialist in retina with some information. 
The commercial activities will be focused on those doctors and will be 
supported by demonstrations, offer of Retmarker free trial periods and on-line 
demonstrations on the site WWW.RETMARKER.COM. 
Another market are the retina specialists ophthalmologists.  
After taking contact with the product and its advantages, as Key Opinion 
Leaders, KOL, they will help us to consolidate the sales growth. 
The commercial department has already initiated the product 
presentation to our clients. 
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10. Awards** 
Retmarker has already won some prizes which is leaving us even more 
hopeful in a good reception from the market. 
 
Coimbra, 4th of March, 2010 – Critical Health S.A. is 
proud to announce that it has won an award in the 
European IT Excellence Awards, an event which 
gathered in London the leading organizations in this 
area. Critical Health won in the category for Information 
Management, with one of its Retmarker product 
(www.retmarker.com). The European Excellence 
Awards are organized by IT Europa, aimed at 
recognizing the crucial part that ISVs (Independent Software Vendors) and 
Solution Providers play in the resolution of their clients‘ real problems. Entities 
from 26 countries competed for this prize. 
 
 
Coimbra, Portugal, 2nd of June, 2010 - Critical Health was distinguished 
yesterday with an Honourable Mention in the COTEC-UNICER Award for 
Innovation Products, an award attributed by the Entrepreneurial Association 
for Innovation (Associação Empresarial para a Inovação - COTEC) and 
UNICER, and supported by the Expresso Newspaper. This award aims to 
recognize the Retmarker product, a Medical Device for decision support in the 
ophthalmology domain from Critical Health, a holding of Critical SGPS devoted 
to the development of groundbreaking technological solutions to prevent loss of 
mobility and vision. This award was presented by Carlos Moreira da Silva, 
Chairman at COTEC, and António Pires de Lima, UNICER‘s President of the 
Executive Board, during the 7th COTEC National Innovation Encounter, which 
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this year was dedicated to the theme ―The Innovator‘s DNA‖, and was held in 
Estoril‘s Congress Centre and had the presence of His Excellency the President 
of the Portuguese Republic, Professor Aníbal Cavaco Silva. 
 
 
11. Conclusion 
 
As it became expressed in all the work, Retmarker is a software that can 
bring major improvements in the diagnosis of retinal diseases. It is a 
recentproduct based in a recent study (a new biomarker for Diabetic 
Retinopathy) and only now has begun its commercialization. The cooperation 
between Critical Health and Oftaltec can be an important asset to be well 
succeed in the market. 
The project was designed thinking that Retmarker would be able to 
analyze images of the Oftaltec equipment Spectralis. For now, such analysis is 
not possible (not to say that will not be in the future). Beyond this setback, there 
were still delays in the commercialization due to the time it took to obtain the CE 
marking (6months). The project then underwent some alterations and the last 
plan was completed. 
Concluding, and taking in account all the difficulties encountered during 
this year, the final result surpasses the student‘s expectations.  
 
11.1 Future Work 
 
Regarding the future work Critical Health has under development the 
Retmarker AMD Research,a new software solution which enables computer-
assisted marking of digital images from patients with Age-related Macular 
Edema (AMD), the main cause of blindness in people over 50 years old in 
developed countries. 
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Another challenging task would be the integration with the camera fundus 
software, so that the export of the images from the software of the device to 
Retmarker is automatic. 
This year they thought I could do it but unfortunately, I do not have the 
skills required for such a huge task. 
 
 
11.2. Final Appreciation  
 
Despite the fact that this wasn‘t my first project choice, I am very satisfied 
with the way it ran. 
Although the thesis had been about Retmarker I was able to do other 
tasks. For example, accompany the technical team of Oftaltec in the 
maintenance of laser equipment.  
The work for the thesis, unlike what was expected, was essentially 
bibliographic research and that helped me to develop autonomy skills. 
Another great opportunity was the possibility to understand the business 
environment in two companies so distinct. This will help me for the next stage of 
my life, which passes through the entry in the work market. 
 
 
 
 
 
 
*confidential studies, not revealed by Critical Health 
**from Critical Health Website 
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Annexes 
 
Annex A – Full quality assurance System 
 
COUNCIL DIRECTIVE 93/42/EEC of 14 June 1993 concerning medical devices 
ANNEX II  
EC DECLARATION OF CONFORMITY (Full quality assurance system)  
1. The manufacturer must ensure application of the quality system approved for the design, 
manufacture and final inspection of the products concerned, as specified in Section 3 and is 
subject to audit as laid down in Sections 3.3 and 4 and to Community surveillance as specified 
in Section 5.  
2. The declaration of conformity is the procedure whereby the manufacturer who fulfils the 
obligations imposed by Section 1 ensures and declares that the products concerned meet the 
provisions of this Directive which apply to them.  
The manufacturer must affix the CE marking in accordance with Article 17 and draw up a 
written declaration of conformity. This declaration must cover a given number of the products 
manufactured and be kept by the manufacturer.  
3. Quality system 
3.1. The manufacturer must lodge an application for assessment of his quality system with a 
notified body.  
The application must include:  
- the name and address of the manufacturer and any additional manufacturing site covered by 
the quality system,  
- all the relevant information on the product or product category covered by the procedure,  
- a written declaration that no application has been lodged with any other notified body for the 
same product-related quality system,  
- the documentation on the quality system,  
- an undertaking by the manufacturer to fulfil the obligations imposed by the quality system 
approved,  
- an undertaking by the manufacturer to keep the approved quality system adequate and 
efficacious,  
- an undertaking by the manufacturer to institute and keep up to date a systematic procedure 
to review experience gained from devices in the post-production phase and to implement 
appropriate means to apply any necessary corrective action. This undertaking must include an 
obligation for the manufacturer to notify the competent authorities of the following incidents 
immediately on learning of them:  
(i) any malfunction or deterioration in the characteristics and/or performance of a device, as 
well as any inadequacy in the instructions for use which might lead to or might have led to the 
death of a patient or user or to a serious deterioration in his state of health;  
(ii) any technical or medical reason connected with the characteristics or performance of a 
device leading for the reasons referred to in subparagraph (i) to systematic recall of devices of 
the same type by the manufacturer.  
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3.2. Application of the quality system must ensure that the products conform to the provisions 
of this Directive which apply to them at every stage, from design to final inspection. All the 
elements, requirements and provisions adopted by the manufacturer for his quality system 
must be documented in a systematic and orderly manner in the form of written policies and 
procedures such as quality programmes, quality plans, quality manuals and quality records.  
It shall include in particular an adequate description of:  
(a) the manufacturer's quality objectives;  
(b) the organization of the business and in particular:  
- the organizational structures, the responsibilities of the managerial staff and their 
organizational authority where quality of design and manufacture of the products is concerned,  
- the methods of monitoring the efficient operation of the quality system and in particular its 
ability to achieve the desired quality of design and of product, including control of products 
which fail to conform;  
(c) the procedures for monitoring and verifying the design of the products and in particular:  
- a general description of the product, including any variants planned,  
- the design specifications, including the standards which will be applied and the results of the 
risk analysis, and also a description of the solutions adopted to fulfil the essential requirements 
which apply to the products if the standards referred to in Article 5 are not applied in full,  
- the techniques used to control and verify the design and the processes and systematic 
measures which will be used when the products are being designed,  
- if the device is to be connected to other device(s) in order to operate as intended, proof must 
be provided that it conforms to the essential requirements when connected to any such 
device(s) having the characteristics specified by the manufacturer,  
- a statement indicating whether or not the device incorporates, as an integral part, a 
substance as referred to in Section 7.4 of Annex I and data on the tests conducted in this 
connection,  
- the clinical data referred to in Annex X,  
- the draft label and, where appropriate, instructions for use;  
(d) the inspection and quality assurance techniques at the manufacturing stage and in 
particular:  
- the processes and procedures which will be used, particularly as regards sterilization, 
purchasing and the relevant documents,  
- the product identification procedures drawn up and kept up to date from drawings, 
specifications or other relevant documents at every stage of manufacture;  
(e) the appropriate tests and trials which will be carried out before, during and after 
manufacture, the frequency with which they will take place, and the test equipment used; it 
must be possible to trace back the calibration of the test equipment adequately.  
3.3. The notified body must audit the quality system to determine whether it meets the 
requirements referred to in Section 3.2. It must presume that quality systems which implement 
the relevant harmonized standards conform to these requirements.  
The assessment team must include at least one number with past experience of assessments 
of the technology concerned. The assessment procedure must include an inspection on the 
manufacturer's premises and, in duly substantiated cases, on the premises of the 
manufacturer's suppliers and/or subcontractors to inspect the manufacturing processes.  
The decision is notified to the manufacturer. It must contain the conclusions of the inspection 
and a reasoned assessment.  
3.4. The manufacturer must inform the notified body which approved the quality system of any 
plan for substantial changes to the quality system or the product-range covered. The notified 
body must assess the changes proposed and verify whether after these changes the quality 
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system still meets the requirements referred to in Section 3.2. It must notify the manufacturer 
of its decision. This decision must contain the conclusions of the inspection and a reasoned 
assessment.  
4. Examination of the design of the product 
4.1. In addition to the obligations imposed by Section 3, the manufacturer must lodge with the 
notified body an application for examination of the design dossier relating to the product which 
he plans to manufacture and which falls into the category referred to in Section 3.1.  
4.2. The application must describe the design, manufacture and performances of the product 
in question. It must include the documents needed to assess whether the product conforms to 
the requirements of this Directive, as referred to in Section 3.2 (c).  
4.3. The notified body must examine the application and, if the product conforms to the 
relevant provisions of this Directive, issue the application with an EC design-examination 
certificate. The notified body may require the application to be completed by further tests or 
proof to allow assessment of conformity with the requirements of the Directive. The certificate 
must contain the conclusions of the examination, the conditions of validity, the data needed for 
identification of the approved design, where appropriate, a description of the intended purpose 
of the product.  
In the case of devices referred to in Annex I, paragraph 7.4, the notified body shall, in view of 
the aspects addressed in that paragraph, consult one of the competent bodies established by 
the Member States in accordance with Directive 65/65/EEC before taking a decision.  
The notified body will give due consideration to the views expressed in this consultation when 
making its decision. It will convey its final decision to the competent body concerned.  
4.4. Changes to the approved design must receive further approval from the notified body 
which issued the EC design-examination certificate wherever the changes could affect 
conformity with the essential requirements of the Directive or with the conditions prescribed for 
use of the product. The applicant shall inform the notified body which issued the EC design-
examination certificate of any such changes made to the approved design. This additional 
approval must take the form of a supplement to the EC design-examination certificate.  
5. Surveillance 
5.1. The aim of surveillance is to ensure that the manufacturer duly fulfils the obligations 
imposed by the approved quality system.  
5.2. The manufacturer must authorize the notified body to carry out all the necessary 
inspections and supply it with all relevant information, in particular:  
- the documentation on the quality system,  
- the data stipulated in the part of the quality system relating to design, such as the results of 
analyses, calculation tests, etc.,  
- the data stipulated in the part of the quality system relating to manufacture, such as 
inspection reports and test data, calibration data, qualification reports of the personnel 
concerned, etc.  
5.3. The notified body must periodically carry out appropriate inspections and assessments to 
make sure that the manufacturer applies the approved quality system and must supply the 
manufacturer with an assessment report.  
5.4. In addition, the notified body may pay unannounced visits to the manufacturer. At the time 
of such visits, the notified body may, where necessary, carry out or ask for tests in order to 
check that the quality system is working properly. It must provide the manufacturer with an 
inspection report and, if a test has been carried out, with a test report.  
6. Administrative provisions 
6.1. The manufacturer must, for a period ending at least five years after the last product has 
been manufactured, keep at the disposal of the national authorities:  
- the declaration of conformity,  
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- the documentation referred to in the fourth indent of Section 3.1,  
- the changes referred to in Section 3.4,  
- the documentation referred to in Section 4.2, and 
- the decisions and reports from the notified body as referred to in Sections 3.3, 4.3, 4.4, 5.3 
and 5.4.  
6.2. The notified body must make available to the other notified bodies and the competent 
authority, on request, all relevant information concerning quality system approvals issued, 
refused or withdrawn.  
6.3. In respect of devices subject to the procedure in Section 4, when neither the manufacturer 
nor his authorized representative is established in the Community, the obligation to keep 
available the technical documentation shall fall to the person responsible for placing the device 
on the Community market or the importer referred to in Annex I, Section 13.3 (a).  
7. Application to devices in Classes IIa and IIb 
In line with Article 11 (2) and (3), this Annex may apply to products in Classes IIa and IIb. 
Section 4, however, does not apply. 
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Annex B – Rules to classify medical devices 
 
COUNCIL DIRECTIVE 93/42/EEC of 14 June 1993 concerning medical devices 
 
ANNEX IX  
CLASSIFICATION CRITERIA I. DEFINITIONS 1. Definitions for the classification rules 
1.1. Duration 
Transient 
Normally intended for continuous use for less than 60 minutes.  
Short term 
Normally intended for continuous use for not more than 30 days.  
Long term 
Normally intended for continuous use for more than 30 days.  
1.2. Invasive devices 
Invasive device 
A device which, in whole or in part, penetrates inside the body, either through a body orifice or 
through the surface of the body.  
Body orifice 
Any natural opening in the body, as well as the external surface of the eyeball, or any 
permanent artificial opening, such as a stoma.  
Surgically invasive device 
An invasive device which penetrates inside the body through the surface of the body, with the 
aid or in the context of a surgical operation.  
For the purposes of this Directive devices other than those referred to in the previous 
subparagraph and which produce penetration other than through an established body orifice, 
shall be treated as surgically invasive devices.  
Implantable device 
Any device which is intended:  
- to be totally introduced into the human body or,  
- to replace an epithelial surface or the surface of the eye,  
by surgical intervention which is intended to remain in place after the procedure.  
Any device intended to be partially introduced into the human body through surgical intervention 
and intended to remain in place after the procedure for at least 30 days is also considered an 
implantable device.  
1.3. Reusable surgical instrument 
Instrument intended for surgical use by cutting, drilling, sawing, scratching, scraping, clamping, 
retracting, clipping or similar procedures, without connection to any active medical device and 
which can be reused after appropriate procedures have been carried out.  
1.4. Active medical device 
Any medical device operation of which depends on a source of electrical energy or any source 
of power other than that directly generated by the human body or gravity and which acts by 
converting this energy. Medical devices intended to transmit energy, substances or other 
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elements between an active medical device and the patient, without any significant change, are 
not considered to be active medical devices.  
1.5. Active therapeutical device 
Any active medical device, whether used alone or in combination with other medical devices, to 
support, modify, replace or restore biological functions or structures with a view to treatment or 
alleviation of an illness, injury or handicap.  
1.6. Active device for diagnosis 
Any active medical device, whether used alone or in combination with other medical devices, to 
supply information for detecting, diagnosing, monitoring or treating physiological conditions, 
states of health, illnesses or congenital deformities.  
1.7. Central circulatory system 
For the purposes of this Directive, 'central circulatory system' means the following vessels:  
arteriae pulmonales, aorta ascendens, arteriae coronariae, arteria carotis communis, arteria 
carotis externa, arteria carotis interna, arteriae cerebrales, truncus brachicephalicus, venae 
cordis, venae pulmonales, vena cava superior, vena cava inferior.  
1.8. Central nervous system 
For the purposes of this Directive, 'central nervous system' means brain, meninges and spinal 
cord.  
II. IMPLEMENTING RULES 2. Implementing rules 
2.1. Application of the classification rules shall be governed by the intended purpose of the 
devices.  
2.2. If the device is intended to be used in combination with another device, the classification 
rules shall apply separately to each of the devices. Accessories are classified in their own right 
separately from the device with which they are used.  
2.3. Software, which drives a device or influences the use of a device, falls automatically in the 
same class.  
2.4. If the device is not intended to be used solely or principally in a specific part of the body, it 
must be considered and classified on the basis of the most critical specified use.  
2.5. If several rules apply to the same device, based on the performance specified for the device 
by the manufacturer, the strictest rules resulting in the higher classification shall apply.  
III. CLASSIFICATION 1. Non-invasive devices 
1.1. Rule 1 
All non-invasive devices are in Class I, unless one of the rules set out hereinafter applies.  
1.2. Rule 2 
All non-invasive devices intended for channelling or storing blood, body liquids or tissues, liquids 
or gases for the purpose of eventual infusion, administration or introduction into the body are in 
Class IIa:  
- if they may be connected to an active medical device in Class IIa or a higher class,  
- if they are intended for use for storing or channelling blood or other body liquids or for storing 
organs, parts of organs or body tissues,  
in all other cases they are in Class I.  
1.3. Rule 3 
All non-invasive devices intended for modifying the biological or chemical composition of blood, 
other body liquids or other liquids intended for infusion into the body are in Class IIb, unless the 
treatment consists of filtration, centrifugation or exchanges of gas, heat, in which case they are 
in Class IIa.  
1.4. Rule 4 
  
Launch of the application Retmarker  47 
 
All non-invasive devices which come into contact with injured skin:  
- are in Class I if they are intended to be used as a mechanical barrier, for compression or for 
absorption of exudates,  
- are in Class IIb if they are intended to be used principally with wounds which have breached 
the dermis and can only heal by secondary intent,  
- are in Class IIa in all other cases, including devices principally intended to manage the micro-
environment of a wound.  
2. Invasive devices 
2.1. Rule 5 
All invasive devices with respect to body orifices, other than surgically invasive devices and 
which are not intended for connection to an active medical device:  
- are in Class I if they are intended for transient use,  
- are in Class IIa if they are intended for short-term use, except if they are used in the oral cavity 
as far as the pharynx, in an ear canal up to the ear drum or in a nasal cavity, in which case they 
are in Class I,  
- are in Class IIb if they are intended for long-term use, except if they are used in the oral cavity 
as far as the pharynx, in an ear canal up to the ear drum or in a nasal cavity and are not liable to 
be absorbed by the mucous membrane, in which case they are in Class IIa.  
All invasive devices with respect to body orifices, other than surgically invasive devices, 
intended for connection to an active medical device in Class IIa or a higher class, are in Class 
IIa.  
2.2. Rule 6 
All surgically invasive devices intended for transient use are in Class IIa unless they are:  
- intended specifically to diagnose, monitor or correct a defect of the heart or of the central 
circulatory system through direct contact with these parts of the body, in which case they are in 
Class III,  
- reusable surgical instruments, in which case they are in Class I,  
- intended to supply energy in the form of ionizing radiation in which case they are in Class IIb,  
- intended to have a biological effect or to be wholly or mainly absorbed in which case they are 
in Class IIb,  
- intended to administer medicines by means of a delivery system, if this is done in a manner 
that is potentially hazardous taking account of the mode of application, in which they are in 
Class IIb.  
2.3. Rule 7 
All surgically invasive devices intended for short-term use are in Class IIa unless they are 
intended:  
- either specifically to diagnose, monitor or correct a defect of the heart or of the central 
circulatory system through direct contact with these parts of the body, in which case they are in 
Class III,  
- or specifically for use in direct contact with the central nervous system, in which case they are 
in Class III,  
- or to supply energy in the form of ionizing radiation in which case they are in Class IIb,  
- or to have a biological effect or to be wholly or mainly absorbed in which case they are in 
Class III,  
- or to undergo chemical change in the body, except if the devices are placed in the teeth, or to 
administer medicines, in which case they are in Class IIb.  
2.4. Rule 8 
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All implantable devices and long-term surgically invasive devices are in Class IIb unless they 
are intended:  
- to be placed in the teeth, in which case they are in Class IIa,  
- to be used in direct contact with the heart, the central circulatory system or the central nervous 
system, in which case they are in Class III,  
- to have a biological effect or to be wholly or mainly absorbed, in which case they are in Class 
III,  
- or to undergo chemical change in the body, except if the devices are placed in the teeth, or to 
administer medicines, in which case they are in Class III.  
3. Additional rules applicable to active devices 
3.1. Rule 9 
All active therapeutic devices intended to administer or exchange energy are in Class IIa unless 
their characteristics are such that they may administer or exchange energy to or from the 
human body in a potentially hazardous way, taking account of the nature, the density and site of 
application of the energy, in which case they are in Class IIb.  
All active devices intended to control or monitor the performance of active therapeutic devices in 
Class IIb, or intended directly to influence the performance of such devices are in Class IIb.  
3.2. Rule 10 
Active devices intended for diagnosis are in Class IIa:  
- if they are intended to supply energy which will be absorbed by the human body, except for 
devices used to illuminate the patient's body, in the visible spectrum,  
- if they are intended to image in vivo distribution of radiopharmaceuticals,  
- if they are intended to allow direct diagnosis or monitoring of vital physiological processes, 
unless they are specifically intended for monitoring of vital physiological parameters, where the 
nature of variations is such that it could result in immediate danger to the patient, for instance 
variations in cardiac performance, respiration, activity of CNS in which case they are in Class 
IIb.  
Active devices intended to emit ionizing radiation and intended for diagnostic and therapeutic 
interventional radiology including devices which control or monitor such devices, or which 
directly influence their performance, are in Class IIb.  
Rule 11 
All active devices intended to administer and/or remove medicines, body liquids or other 
substances to or from the body are in Class IIa, unless this is done in a manner:  
- that is potentially hazardous, taking account of the nature of the substances involved, of the 
part of the body concerned and of the mode of application in which case they are in Class IIb.  
3.3. Rule 12 
All other active devices are in Class I.  
4. Special Rules 
4.1. Rule 13 
All devices incorporating, as an integral part, a substance which, if used separately, can be 
considered to be a medicinal product, as defined in Article 1 of Directive 65/65/EEC, and which 
is liable to act on the human body with action ancillary to that of the devices, are in Class III.  
4.2. Rule 14 
All devices used for contraception or the prevention of the transmission of sexually transmitted 
diseases are in Class IIb, unless they are implantable or long term invasive devices, in which 
case they are in Class III.  
4.3. Rule 15 
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All devices intended specifically to be used for disinfecting, cleaning, rinsing or, when 
appropriate, hydrating contact lenses are in Class IIb.  
All devices intended specifically to be used for disinfecting medical devices are in Class IIa.  
This rule does not apply to products that are intended to clean medical devices other than 
contact lenses by means of physical action.  
4.4. Rule 16 
Non-active devices specifically intended for recording of X-ray diagnostic images are in Class 
IIa.  
4.5. Rule 17 
All devices manufactured utilizing animal tissues or derivatives rendered non-viable are Class III 
except where such devices are intended to come into contact with intact skin only.  
5. Rule 18 
By derogation from other rules, blood bags are in Class IIb. 
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Annex C – Amendments to the Annex II and IX of 93/42/EEC Directive 
 
DIRECTIVE 2007/47/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 
September 2007amending Council Directive 90/385/EEC on the approximation of the laws 
of the Member States relating to active implantable medical devices, Council Directive 
93/42/EEC concerning medical devices and Directive 98/8/EC concerning the placing of 
biocidal products on the market 
 
 
2. Annex II shall be amended as follows: 
(a) Section 2 shall be replaced by the following: 
‗2. The EC declaration of conformity is the procedure whereby the manufacturer who fulfils the 
obligations imposed by Section 1 ensures and declares that the products concerned meet the 
provisions of this Directive which apply to them. 
The manufacturer must affix the CE marking in accordance with Article 17 and draw up a written 
declaration of conformity. This declaration must cover one or more medical devices 
manufactured, clearly identified by means of product name, product code or other unambiguous 
reference and must be kept by the manufacturer.‘; 
(b) in Section 3.1, second paragraph, the introductory part of the seventh indent shall be 
replaced by the following: 
‗— an undertaking by the manufacturer to institute and keep up to date a systematic procedure 
to review  experience gained from devices in the post-production phase, including the 
provisions referred to in Annex X, and to implement appropriate means to apply any necessary 
corrective action. This undertaking must include an obligation for the manufacturer to notify the 
competent authorities of the following incidents immediately on learning of them:‘; 
(c) Section 3.2 shall be amended as follows: 
(i) the following paragraph shall be inserted after the first paragraph: 
‗It shall include in particular the corresponding documentation, data and records arising from the 
procedures referred to in point (c).‘; 
(ii) in point (b), the following indent shall be added: 
‗— where the design, manufacture and/or final inspection and testing of the products, or 
elements thereof, is carried out by a third party, the methods of monitoring the efficient 
operation of the quality system and in particular the type and extent of control applied to the 
third party;‘ 
 (iii) point (c) shall be replaced by the following: 
‗(c) the procedures for monitoring and verifying the design of the products, including the 
corresponding documentation, and in particular: 
— a general description of the product, including any variants planned, and its intended use(s), 
— the design specifications, including the standards which will be applied and the results of the 
risk analysis, and also a description of the solutions adopted to fulfil the essential requirements 
which apply to the products if the standards referred to in Article 5 are not applied in full, 
— the techniques used to control and verify the design and the processes and systematic 
measures which will be used when the products are being designed, 
— if the device is to be connected to other device(s) in order to operate as intended, proof must 
be provided that it conforms to the essential requirements when connected to any such device 
(s) having the characteristics specified by the manufacturer, 
— a statement indicating whether or not the device incorporates, as an integral part, a 
substance or a human blood derivative referred to in section 7.4 of Annex I and the data on the 
tests conducted in this connection required to assess the safety, quality and usefulness of that 
substance or human blood derivative, taking account of the intended purpose of the device, 
— a statement indicating whether or not the device is manufactured utilising tissues of animal 
origin as referred to in Commission Directive 2003/32/EC (*), 
— the solutions adopted as referred to in Annex I, Chapter I, Section 2, 
— the pre-clinical evaluation, 
— the clinical evaluation referred to in Annex X, 
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— the draft label and, where appropriate, instructions for use. 
(*) Commission Directive 2003/32/EC of 23 April 2003 introducing detailed specifications as 
regards the requirements laid down in Council Directive 93/42/EEC with respect to medical 
devices manufactured utilising tissues of animal origin (OJ L 105, 26.4.2003, p. 18).‘ 
(d) the second paragraph of Section 3.3 shall be replaced by the following: 
‗The assessment team must include at least one member with past experience of assessments 
of the technology concerned. The assessment procedure must include an assessment, on a 
representative basis, of the documentation of the design of the product(s) concerned, an 
inspection on the manufacturer's premises and, in duly substantiated cases, on the premises of 
the manufacturer's suppliers and/or subcontractors to inspect the manufacturing processes.‘; 
(e) in Section 4.3, the second and third paragraphs shall be replaced by the following: 
‗In the case of devices referred to in Annex I, Section 7.4, second paragraph, the notified body 
shall, as regards the aspects referred to in that section, consult one of the competent authorities 
designated by the Member States in accordance with Directive 2001/83/EC or the EMEA before 
taking a decision. The opinion of the competent national authority or the EMEA must be drawn 
up within 210 days after receipt of valid documentation. The scientific opinion of the competent 
national authority or the EMEA must be included in the documentation concerning the device. 
The notified body will give due consideration to the views expressed in this consultation when 
making its decision. It will convey its final decision to the competent body concerned. 
In the case of devices referred to in Annex I, Section 7.4, third paragraph, the scientific opinion 
of the EMEA must be included in the documentation concerning the device. The opinion of the 
EMEA must be drawn up within 210 days after receipt of valid documentation. The notified body 
will give due consideration to the opinion of the EMEA when making its decision. The notified 
body may not deliver the certificate if the EMEA's scientific opinion is unfavourable. It will 
convey its final decision to the EMEA. 
In the case of devices manufactured utilising tissues of animal origin as referred to in Directive 
2003/32/EC, the notified body must follow the procedures referred to in that Directive.‘; 
(f) in Section 5.2, the second indent shall be replaced by the following: 
‗— the data stipulated in the part of the quality system relating to design, such as the results of 
analyses, 
calculations, tests, the solutions adopted as referred to in Annex I, Chapter I, Section 2, pre-
clinical and clinical evaluation, post-market clinical follow-up plan and the results of the post-
market clinical followup, if applicable, etc.,‘; 
(g) Section 6.1 shall be amended as follows: 
(i) the introductory part shall be replaced by the following: 
‗The manufacturer or his authorised representative must, for a period ending at least five years, 
and in the case of implantable devices at least 15 years, after the last product has been 
manufactured, keep at the disposal of the national authorities:‘; 
(ii) the following phrase shall be added to the second indent: 
‗and in particular the documentation, data and records referred to in the second paragraph of 
Section 3.2,‘; 
(h) Section 6.3 shall be deleted; 
(i) Section 7 shall be replaced by the following: 
‗7. Application to devices in Classes IIa and IIb. 
7.1. In line with Article 11(2) and (3), this Annex may apply to products in Classes IIa and IIb. 
Section 4, however, does not apply. 
7.2. For devices in Class IIa the notified body shall assess, as part of the assessment in Section 
3.3, the technical documentation as described in Section 3.2(c) for at least one representative 
sample for each device subcategory for compliance with the provisions of this Directive. 
7.3. For devices in Class IIb the notified body shall assess, as part of the assessment in Section 
3.3, the technical documentation as described in Section 3.2(c) for at least one representative 
sample for each generic device group for compliance with the provisions of this Directive. 
7.4. In choosing representative sample(s) the notified body shall take into account the novelty of 
the technology, similarities in design, technology, manufacturing and sterilisation methods, the 
intended use and the results of any previous relevant assessments (e.g. with regard to physical, 
chemical or biological properties) that have been carried out in accordance with this Directive. 
The notified body shall document and keep available to the competent authority its rationale for 
the sample(s) taken. 
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7.5. Further samples shall be assessed by the notified body as part of the surveillance 
assessment referred to in Section 5.‘; 
(j) in Section 8, the words ‗Article 4(3) of Directive 89/381/EEC‘ shall be replaced by the words 
‗Article 114(2) of Directive 2001/83/EC‘; 
 
 
 
 
 
 
 
 
 
Annex IX shall be amended as follows: 
(a) Chapter I shall be amended as follows: 
(i) in Section 1.4, the following sentence shall be added: 
‗Stand alone software is considered to be an active medical device.‘; 
(ii) Section 1.7 shall be replaced by the following: 
‗1.7. Central circulatory system 
For the purposes of this Directive, ―central circulatory system‖ means the following vessels: 
arteriae pulmonales, aorta ascendens, arcus aorta, aorta descendens to the bifurcatio aortae, 
arteriae 
coronariae, arteria carotis communis, arteria carotis externa, arteria carotis interna, arteriae 
cerebrales, truncus brachiocephalicus, venae cordis, venae pulmonales, vena cava superior, 
vena 
cava inferior.‘; 
 
(b) in Chapter II, Section 2, the following section shall be added: 
‗2.6. In calculating the duration referred to in Section 1.1 of Chapter I, continuous use means 
―an uninterrupted 
actual use of the device for the intended purpose‖. However where usage of a device is 
discontinued in 
order for the device to be replaced immediately by the same or an identical device this shall be 
considered 
an extension of the continuous use of the device.‘; 
(c) Chapter III shall be amended as follows: 
(i) the introductory phrase of the first paragraph of Section 2.1 shall be replaced by the 
following: 
‗All invasive devices with respect to body orifices, other than surgically invasive devices and 
which are not 
intended for connection to an active medical device or which are intended for connection to an 
active 
medical device in Class I:‘; 
(ii) Section 2.2 shall be replaced by the following: 
‗2.2. Rule 6 
All surgically invasive devices intended for transient use are in Class IIa unless they are: 
— intended specifically to control, diagnose, monitor or correct a defect of the heart or of the 
central circulatory system through direct contact with these parts of the body, in which case 
they are in Class III, 
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— reusable surgical instruments, in which case they are in Class I, 
— intended specifically for use in direct contact with the central nervous system, in which case 
they are in Class III, 
— intended to supply energy in the form of ionising radiation in which case they are in Class IIb, 
— intended to have a biological effect or to be wholly or mainly absorbed in which case they are 
in Class IIb, 
— intended to administer medicines by means of a delivery system, if this is done in a manner 
that is potentially hazardous taking account of the mode of application, in which case they are 
in Class IIb.‘; 
(iii) in Section 2.3, the first indent shall be replaced by the following: 
‗— either specifically to control, diagnose, monitor or correct a defect of the heart or of the 
central 
circulatory system through direct contact with these parts of the body, in which case they are in 
Class III,‘; 
(iv) in Section 4.1, first paragraph, the reference ‗65/65/EEC‘ shall be replaced by the reference 
‗2001/83/EC‘; 
(v) in Section 4.1, the second paragraph shall be replaced by the following: 
‗All devices incorporating, as an integral part, a human blood derivative are in Class III.‘; 
(vi) in Section 4.3, second paragraph, the following phrase shall be added: 
‗unless they are specifically to be used for disinfecting invasive devices in which case they are 
in Class IIb.‘; 
(vii) in Section 4.4, the words ‗Non-active devices‘ shall be replaced by the word ‗Devices‘; 
 
 
 
 
 
 
 
